Hongliang Shi

发表

Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone.

G. Mulligan, D. Esseltine, P. Sonneveld, 2012, Blood.

The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial.

J. Sylvester, F. Saad, D. Dearnaley, 2020, European urology.

2502 TAK-385, an oral GnRH antagonist: efficacy and safety results from a randomized phase 2 trial in prostate cancer patients (pts)

F. Saad, N. Shore, C. Pieczonka, 2015 .

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.

J. Leonard, S. de Vos, R. Fisher, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical efficacy comparison of avapritinib with other tyrosine kinase inhibitors in gastrointestinal stromal tumors with PDGFRA D842V mutation: a retrospective analysis of clinical trial and real-world data

G. Hoehn, M. Heinrich, M. von Mehren, 2021, BMC Cancer.

Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.

Yoon-Koo Kang, K. Hoeflich, C. Lengauer, 2019, Cancer discovery.

A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma

D. Esseltine, K. Anderson, P. Sonneveld, 2017, British journal of haematology.

Novel Three- and Four-Drug Combination Regimens of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Previously Untreated Multiple Myeloma: Results From the Multi-Center, Randomized, Phase 2 EVOLUTION Study

I. Flinn, G. Mulligan, P. Richardson, 2010 .

Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib‐melphalan‐prednisone in the phase III VISTA study

M. Dimopoulos, A. Palumbo, P. Richardson, 2015, American journal of hematology.

First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant Fibroblast Growth Factor 19 Signaling as a Driver Event in Hepatocellular Carcinoma.

Nicolas Stransky, V. Mazzaferro, J. Llovet, 2019, Cancer discovery.

Authors’ Response

J. S. San Miguel, M. Mateos, Hongliang Shi, 2015, American journal of hematology.

Quantifying The Risk Of Heart Failure Associated With Proteasome Inhibition: A Retrospective Analysis Of Heart Failure Reported In Phase 2 and Phase 3 Studies Of Bortezomib (Btz) In Multiple Myeloma (MM)

D. Esseltine, P. Sonneveld, S. Lonial, 2013 .

Bortezomib, Bendamustine, and Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma: Encouraging Activity in the Phase 2 VERTICAL Study.

Sonali M. Smith, B. Cheson, Michael E. Williams, 2009 .

Meta-analysis of the efficacy and safety of bortezomib re-treatment in patients with multiple myeloma.

K. Knopf, M. Duh, R. Comenzo, 2014, Clinical lymphoma, myeloma & leukemia.

Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma.

I. Flinn, G. Mulligan, P. Richardson, 2012, Blood.

Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study.

Sonali M. Smith, B. Cheson, Michael E. Williams, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Novel Three– and Four–Drug Combinations of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Newly Diagnosed Multiple Myeloma: Encouraging Results From the Multi-Center, Randomized, Phase 2 EVOLUTION Study.

I. Flinn, P. Richardson, P. Hari, 2009 .

Second interim analysis (IA2) results from a phase II trial of TAK-385, an oral GnRH antagonist, in prostate cancer patients (pts).

F. Saad, N. Shore, C. Pieczonka, 2016 .

Recommendations for safety planning, data collection, evaluation and reporting during drug, biologic and vaccine development: a report of the safety planning, evaluation, and reporting team

Jesse A Berlin, Devan V Mehrotra, H Amy Xia, 2009, Clinical trials.

Potential biomarkers of bortezomib activity in mantle cell lymphoma from the phase 2 PINNACLE trial

G. Mulligan, R. Fisher, M. Fleming, 2010, Leukemia & lymphoma.

Medical Castration Using the Investigational Oral GnRH Antagonist TAK-385 (Relugolix): Phase 1 Study in Healthy Males.

F. Saad, H. Faessel, H. Shi, 2015, The Journal of clinical endocrinology and metabolism.

PD28-01 TESTOSTERONE LOWERING, PSA RESPONSE AND QUALITY OF LIFE IN PATIENTS WITH ADVANCED HORMONE SENSITIVE PROSTATE CANCER RECEIVING TAK-385, AN ORAL GNRH ANTAGONIST: PHASE 2 INTERIM ANALYSIS

F. Saad, N. Shore, C. Pieczonka, 2016 .

G. Hoehn, M. Heinrich, M. von Mehren, 2021, BMC cancer.

Safety and Efficacy of Novel Combination Therapy with Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide in Newly Diagnosed Multiple Myeloma: Initial Results from the Phase I/II Multi-Center EVOLUTION Study

I. Flinn, A. Krishnan, P. Richardson, 2008 .

The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment.

L. Garrison, H. van de Velde, M. Duh, 2013, The oncologist.

Patient Perceptions in Mast Cell Disorders.

S. Verstovsek, T. George, R. Zack, 2018, Immunology and allergy clinics of North America.

Systemic Mastocytosis Patient Experience from Mast Cell Connect, the First Patient-Reported Registry for Mastocytosis

S. Verstovsek, A. Boral, T. George, 2016 .

Clinical Activity in a Phase 1 Study of Blu-285, a Potent, Highly-Selective Inhibitor of KIT D816V in Advanced Systemic Mastocytosis (AdvSM)

S. Verstovsek, M. Deininger, D. DeAngelo, 2017 .

Preliminary Safety and Clinical Activity in a Phase 1 Study of Blu-285, a Potent, Highly-Selective Inhibitor of KIT D816V in Advanced Systemic Mastocytosis (SM)

S. Verstovsek, M. Deininger, D. DeAngelo, 2016 .

Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: Phase 1 dose-escalation study

R. Kurzrock, Sunil Sharma, D. Hong, 2014, Investigational New Drugs.

Meta-Analysis of the Efficacy and Safety of Bortezomib Retreatment in Patients with Multiple Myeloma (MM)

K. Knopf, M. Duh, R. Comenzo, 2012 .

Abstract CT043: Highly potent and selective RET inhibitor, BLU-667, achieves proof of concept in a phase I study of advanced,RET-altered solid tumors

S. Ou, M. Brose, V. Subbiah, 2018, Clinical Trials.

previously untreated multiple myeloma of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in Randomized, multicenter, phase 2 study (EVOLUTION) of combinations

G. Mulligan, P. Richardson, P. Hari, 2012 .

Effectiveness and Cost-Utility Analysis of Different Doses of Irinotecan Plus Bevacizumab in Patients With Metastatic Colorectal Cancer: A Long-Term and Prospective Cohort Study

Jaw-Yuan Wang, H. Tsai, Yen-Cheng Chen, 2022, Frontiers in Oncology.

First-in-human study of BLU-554, a potent, highly-selective FGFR4 inhibitor designed for hepatocellular carcinoma (HCC) with FGFR4 pathway activation

J. Llovet, S. Choo, T. Meyer, 2016 .

Clinical activity of BLU-285 in advanced gastrointestinal stromal tumor (GIST).

Robin L. Jones, O. Mir, M. Heinrich, 2017 .

S830 AVAPRITINIB, A POTENT AND SELECTIVE INHIBITOR OF KIT D816V, INDUCES COMPLETE AND DURABLE RESPONSES IN PATIENTS (PTS) WITH ADVANCED SYSTEMIC MASTOCYTOSIS (ADVSM)

M. Deininger, T. George, D. DeAngelo, 2019, HemaSphere.

Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study.

J. Leonard, S. de Vos, R. Fisher, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study

I. Flinn, A. Krishnan, P. Richardson, 2010, Leukemia.

Preliminary safety and activity in a first-in-human phase 1 study of BLU-285, a potent, highly-selective inhibitor of KIT and PDGFRα activation loop mutants in advanced gastrointestinal stromal tumor (GIST)

Robin L. Jones, O. Mir, M. Heinrich, 2016 .